What is Dabrico?
Dabrico operates at the intersection of artificial intelligence and industrial automation, specifically targeting the rigorous demands of the pharmaceutical industry. The company specializes in advanced visual inspection machines designed to detect defects in injectable products with high precision. By integrating intelligent automation into the quality control workflow, Dabrico addresses critical regulatory compliance challenges while simultaneously enhancing operational throughput. Their comprehensive product suite, which spans automated, semi-automated, and manual inspection systems, positions the firm as a vital partner for manufacturers seeking to minimize human error and optimize production line reliability in a highly regulated environment.
How much funding has Dabrico raised?
Dabrico has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Dabrico
PPP
Public-Private Partnership
What's next for Dabrico?
With this late-stage financing secured, Dabrico is well-positioned to accelerate its research and development initiatives, particularly in the realm of deep-learning-based defect detection. The strategic allocation of these funds will likely focus on expanding the company's international footprint and enhancing its auxiliary equipment offerings, such as syringe stopper insertion systems. As the pharmaceutical sector continues to prioritize automated quality assurance, Dabrico's commitment to innovation suggests a robust growth trajectory. The firm is expected to leverage this capital to deepen its market penetration, ensuring that its technological solutions remain at the forefront of pharmaceutical manufacturing standards and regulatory requirements.
See full Dabrico company page
